Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Fidaxomicin is an antibiotic developed by Optimer, which targets the unique mechanism of refractory Clostridium and can effectively inhibit RNA polymerase, ensuring clinically effi···【more】
Article source：Captain MedicineRelease date：2024-08-29Recommended：265
Fidaxomicin is an innovative macrolide antibiotic developed by Optimer, which is designed for the treatment of refractory Clostridium infections with its unique RNA polymerase inhi···【more】
Article source：Captain MedicineRelease date：2024-08-29Recommended：285
Fidaxomicinis an innovative antibiotic designed to treat diarrhea caused by Clostridium difficile by inhibiting bacterial growth through a unique mechanism that reduces interferenc···【more】
Article source：Captain MedicineRelease date：2024-08-29Recommended：340
Fidaxomicin is an innovative antibiotic designed to treat diarrhea caused by Clostridium difficile by inhibiting bacterial growth through a unique mechanism that reduces interferen···【more】
Article source：Captain MedicineRelease date：2024-08-28Recommended：297
Fidaxomicin is a new macrolide antibiotic used for the treatment of Clostridium difficile-associated diarrhea by inhibiting bacterial RNA polymerase and has little effect on the no···【more】
Article source：Captain MedicineRelease date：2024-08-28Recommended：345
Stiripentol is a drug that reduces seizures by modulating GABA receptors, especially for patients with Dravet syndrome. It has demonstrated significant efficacy in clinical trials,···【more】
Article source：Captain MedicineRelease date：2024-08-28Recommended：297
Stiripentol was approved by the FDA in 2018 for significantly improving seizure frequency and improving the quality of life of infants and young children suffering from Dravet synd···【more】
Article source：Captain MedicineRelease date：2024-08-28Recommended：306
Patients with Dravet syndrome often find it difficult to control seizures with traditional drugs, and Stiripentol, as a new type of drug, has shown significant clinical effects by ···【more】
Article source：Captain MedicineRelease date：2024-08-28Recommended：262
Stiripentol provides new hope for patients with epilepsy that cannot be effectively controlled by enhancing the action of GABA receptors for the treatment of seizures in Dravet syn···【more】
Article source：Captain MedicineRelease date：2024-08-28Recommended：272
Stiripentol is specifically used in the treatment of Dravet syndrome-related seizures by modulating GABA receptors and reducing the frequency of generalized clonic seizures. Clinic···【more】
Article source：Captain MedicineRelease date：2024-08-28Recommended：282
Dravet syndrome is a rare and refractory epileptic encephalopathy, and Stiripentol is widely used to improve the seizure status of patients by inhibiting the hepatocytochrome P450 ···【more】
Article source：Captain MedicineRelease date：2024-08-28Recommended：260
Stiripentol is an innovative antiepileptic drug used to treat Dravet syndrome, mainly by enhancing GABAergic nerve conduction and reducing the frequency of seizures in patients. In···【more】
Article source：Captain MedicineRelease date：2024-08-28Recommended：242
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：2272025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：4542024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：2342025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：2472025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：2272025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：2582025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：2382025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：2182025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
